Consensus CONMED Corporation

Stocks

CNMD

US2074101013

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 12:34:38 26/06/26 am AEST			5-day change	1st Jan Change
35.69 ^USD	+0.82%		+10.04%	-11.70%

18/06	CONMED Names Former Certara CFO John Gallagher as Finance Chief	MT
18/06	CONMED Corporation Appoints John E. Gallagher as Executive Vice President, Principal Financial Officer and Principal Accounting Officer, Effective July 15, 2026	CI

Evolution of the Average Target: CONMED Corporation

Evolution of the Target Price: CONMED Corporation

Changes in Analyst Recommendations: CONMED Corporation

97e4c4c925.KdHqdPvoXtquXHuW4_8uFYatjR0_itgmkH6KDFlmiuc.UbLdHZ66B-rvEBTUmrdNf__UziVp0u5k0RTraCFT-6lms6RDmaNmic8bOg~872548549853e04fca6c6a6a8cb281e7

Analysts' recommendations: CONMED Corporation

18/05	BofA Securities Adjusts CONMED Price Target to $40 From $52	MT
17/03	Piper Sandler Downgrades CONMED to Neutral From Overweight, Adjusts PT to $39 From $55	MT
13/06/25	Conmed Shares Fall After Needham Downgrade	MT
12/06/25	Needham Downgrades CONMED to Hold From Buy, Removes $61 Price Target	MT
28/04/25	Stifel Downgrades CONMED to Hold From Buy, Adjusts Price Target to $55 From $75	MT
07/02/25	JPMorgan Downgrades CONMED to Neutral From Overweight, Adjusts Price Target to $70 From $85	MT
01/08/24	Needham Adjusts CONMED's Price Target to $97 From $106, Keeps Buy Rating	MT
25/07/24	Needham Trims Price Target on CONMED to $106 From $107, Keeps Buy Rating	MT
26/04/24	Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating	MT
25/04/24	Needham Lowers Price Target on CONMED to $107 From $129, Notes Slight Guidance Cut Due to Currency, Keeps Buy Rating	MT
02/02/24	Needham Adjusts Price Target on CONMED to $129 From $119, Maintains Buy Rating	MT
02/02/24	JPMorgan Cuts CONMED Price Target to $115 From $135, Maintains Overweight Rating	MT
27/10/23	Piper Sandler Adjusts Price Target on CONMED to $130 From $145, Maintains Overweight Rating	MT
27/10/23	Wells Fargo Cuts Price Target on CONMED to $107 From $123, Maintains Equalweight Rating	MT
27/07/23	Needham Adjusts Price Target on CONMED to $140 From $139, Maintains Buy Rating	MT
27/07/23	Keybanc Adjusts Price Target on CONMED to $141 From $131, Maintains Overweight Rating	MT
05/06/23	Needham Raises Price Target on CONMED to $139 From $135, Keeps Buy Rating	MT
22/05/23	CL King Starts CONMED at Buy With $140 Price Target	MT
28/04/23	Piper Sandler Raises CONMED's Price Target to $128 From $118, Maintains Overweight Rating	MT
28/04/23	Wells Fargo Adjusts Price Target on CONMED to $119 From $96, Maintains Equal-Weight Rating	MT
27/04/23	Needham Adjusts Price Target on CONMED to $135 From $122, Reiterates Buy Rating	MT
27/04/23	Keybanc Adjusts Price Target on CONMED to $131 From $124, Maintains Overweight Rating	MT
27/03/23	CONMED Upgraded by KeyBanc to Overweight From Sector Weight, Price Target Set at $124; Firm Sees Financial Profile Improving	MT
27/03/23	Analyst recommendations: Caterpillar, Conmed, Corning, Model N, United Rentals...
04/02/23	Needham Raises Price Target on CONMED to $122 From $106, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
CONMED CORPORATION	-	+11.86%
ABBOTT LABORATORIES		+28.79%
MEDTRONIC PLC		+22.3%
HOYA CORPORATION		+15.29%
CENCORA, INC.		+23.39%
BECTON, DICKINSON AND COMPANY		+20.29%
MEDLINE INC.		+41.88%
DEXCOM, INC.		+22.21%
WEST PHARMACEUTICAL SERVICES, INC.		+5.4%
TERUMO CORPORATION		+35.99%
Average		+22.74%
Weighted average by Cap.		+24.38%